Evidence map›Paper›PMID 17672906›Full record

ArticleHealth and quality of life outcomes2007

Validation of two generic patient-reported outcome measures in patients with type 2 diabetes.

Louis S Matza, Kristina S Boye, Nicole Yurgin

Registry-linked trialAbstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Health and quality of life outcomes, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01025076 (Phase II Study of Evaluation of the Safety and Effectiveness of Stomaphyx for Transoral Incisionless Reduction of the Enlarged Gastric Pouch and Stoma), which is not on this map. Cited by 23 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01025076 phase2completednot on this mapstarted 2009, after this paper: background citation

Phase II Study of Evaluation of the Safety and Effectiveness of Stomaphyx for Transoral Incisionless Reduction of the Enlarged Gastric Pouch and Stoma

TypeinterventionalSponsorUniversity of AlbertaRan2009 to 2012Enrolled14ConditionsMorbid ObesityArmsStomaphyX
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Health-related quality of life in racial and ethnic minority adults with type 2 diabetes: validity and responsiveness of the EQ-5D-3L.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Emerging utility of once-weekly exenatide in patients with type 2 diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2015
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Louis S MatzaCenter for Health Outcomes Research at United BioSource Corporation, Bethesda, MD, USA. louis.matza@unitedbiosource.com
Kristina S Boye
Nicole Yurgin

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrior to using a generic patient-reported outcome measure (PRO), the measure should be validated within the target population. The purpose of the current study was to validate two generic measures in patients with type 2 diabetes.

methodsPatients with type 2 diabetes in Scotland and England completed two generic measures: EQ-5D and Psychological General Well-Being Index (PGWB). Two diabetes-specific measures were administered: ADS and DSC-R. Analyses assessed reliability and validity.

resultsThere were 130 participants (53 Scotland; 77 England; 64% male; mean age = 55.7 years). Responses on the EQ-5D and PGWB reflected moderate impairment consistent with previous diabetes samples: mean EQ-5D Index score, 0.75; EQ-5D VAS, 68.8; PGWB global score, 67.9. All scales of the PGWB demonstrated good internal consistency reliability (Cronbach's alpha = 0.77 to 0.97). The EQ-5D and PGWB demonstrated convergent validity through significant correlations with the ADS (r = 0.48 to 0.61), DSC-R scales (r = 0.33 to 0.81 except ophthalmology subscale), and Body Mass Index (r = 0.15 to 0.38). The EQ-5D and PGWB discriminated between groups of patients known to differ in diabetes-related characteristics (e.g., history of hypoglycemia).

conclusionResults support the use of the EQ-5D and PGWB among patients with type 2 diabetes, possibly in combination with condition-specific measures.

Indexed as

Outcome Assessment, Health CareSickness Impact ProfileSurveys and QuestionnairesActivities of Daily LivingAdultAgedDiabetes Mellitus, Type 2EnglandFemaleHumansMaleMiddle AgedPsychometricsQuality of LifeScotlandSocioeconomic Factors

Identifiers

PMID17672906
PMCPMC2042494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.